Effect of hepatic impairment on pharmacokinetics, safety, and tolerability of lemborexant

• Prif Awduron: Satish Dayal (Awdur), Jagadeesh Aluri (Awdur), Nancy Hall (Awdur), Gleb Filippov (Awdur), Margaret Moline (Awdur), Larisa Reyderman (Awdur), Ishani Landry (Awdur)
• Fformat: Llyfr
• Cyhoeddwyd: Wiley, 2021-04-01T00:00:00Z.
• Pynciau: article
• Mynediad Ar-lein: Connect to this object online.

Abstract Lemborexant, a dual orexin receptor antagonist, is approved in the United States, Japan, and Canada for the treatment of insomnia in adults. This phase I, multicenter, open‐label, parallel‐group study assessed the impact of mild or moderate hepatic impairment (HI) on lemborexant pharmacokin...